Cyclacel Pharma Gets Two Patents Extending Exclusivity Of Sapacitabine

(RTTNews) - Cyclacel Pharmaceuticals, Inc. (CYCC, CYCCP) announced that the US Patent and Trademark Office (USPTO) has issued two patents extending the exclusivity of sapacitabine, the company's lead clinical candidate.

The first patent claims, among others, methods of treating cancer comprising sapacitabine together with DNA methyltransferase inhibitors, including azacitidine and decitabine. The second patent claims methods of use for sapacitabine for the treatment of acute myeloid leukemia and myelodysplastic syndromes, including the dosing regimen used in SEAMLESS, the company's ongoing, pivotal, registration-directed, Phase 3 study in front-line elderly acute myeloid leukemia.

"The two new US patents are important enhancements to the sapacitabine intellectual property estate extending existing patent protection, including composition of matter, dosing regimen and combination treatment," said Spiro Rombotis, President and Chief Executive Officer of Cyclacel.